CUHK
News Centre

The Chinese University of Hong Kong (CUHK)’s InnoHK Centre for Neuromusculoskeletal Restorative Medicine (CNRM) and Beijing Gingko Group (BGG), a global company dedicated to developing high-quality, active, natural ingredients, signed a Memorandum of Understanding (MoU) today (12 December). The agreement establishes a three-year collaboration to integrate advanced biomedical validation technologies into the development of dietary supplements, pharmaceuticals and personal care products. This partnership represents a significant advancement in translating rigorous academic research into commercially viable, evidence-based health solutions and is a concrete achievement of the InnoHK initiative.

The MoU was signed by Professor Patrick Yung Shu-hang, JP, Director of CNRM, and Mr Li Chunhua, founder of BGG, and witnessed by the founder of Senelixir Biotech Ltd Professor Wang Huating and BGG Global CEO Mr Li Kun.

CNRM, supported by the InnoHK initiative of the Innovation and Technology Commission (ITC) of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China, possesses a powerful research platform for biomedical validation, featuring multidisciplinary expertise and patented technologies such as oxygen concentration probes and New Alternative Methodologies (NAM). Leveraging multiple proprietary capabilities, CNRM will lead the scientific validation of high-value natural ingredients from the perspective of cutting-edge science, delving into their deep biological mechanisms to promote the development of evidence-based health products. The partnership enhances the credibility of CNRM’s technologies and establishes new industry standards, creating significant commercialisation opportunities.

Concurrently, BGG signed a contract research service agreement with CNRM’s spin-off company Senelixir Biotech Ltd, which represents an important translational milestone ahead of the joint development of supplements targeting sarcopenia, a significant global challenge in ageing. The agreement demonstrates the immediate practical application of the collaboration.

Professor Yung said: “The partnership with BGG establishes a crucial industrial validation platform for CNRM’s patented technologies. By applying and testing those technologies in real-world product development, it not only achieves the leap from academic patents to recognised industry standards but also lays the groundwork for breakthrough advancements in verification technologies for nutraceuticals and pharmaceuticals, aiming to set new innovative industry benchmarks for evidence-based health products.”